Cargando…
ICS-formoterol reliever versus ICS and short-acting β(2)-agonist reliever in asthma: a systematic review and meta-analysis
BACKGROUND: The Global Initiative for Asthma recommends as-needed inhaled corticosteroid (ICS)-formoterol as an alternative to maintenance ICS plus short-acting β(2)-agonist (SABA) reliever at step 2 of its stepwise treatment algorithm. Our aim was to assess the efficacy and safety of these two trea...
Autores principales: | Hatter, Lee, Bruce, Pepa, Braithwaite, Irene, Holliday, Mark, Fingleton, James, Weatherall, Mark, Beasley, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836558/ https://www.ncbi.nlm.nih.gov/pubmed/33532465 http://dx.doi.org/10.1183/23120541.00701-2020 |
Ejemplares similares
-
Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials
por: Hatter, Lee, et al.
Publicado: (2022) -
Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma
por: Fingleton, James, et al.
Publicado: (2017) -
Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
por: Beasley, Richard, et al.
Publicado: (2019) -
The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma
por: Hatter, Lee, et al.
Publicado: (2021) -
Over-the-counter Dispensing: Widening Access to Inhaled Corticosteroid/Formoterol Reliever Therapy
por: Beasley, Richard, et al.
Publicado: (2022)